From PsychonautWiki
(Redirected from 4-aco-mipt)
Jump to navigation Jump to search
Summary sheet: 4-AcO-MiPT
Chemical Nomenclature
Common names 4-AcO-MiPT, Mipracetin, O-Acetylmiprocin
Substitutive name 4-Acetoxy-N-isopropyl-N-methyltryptamine
Systematic name [3-[2-[Isopropyl(methyl)amino]ethyl]-1H-indol-4-yl] acetate
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 5 mg
Light 10 - 15 mg
Common 15 - 20 mg
Strong 20 - 35 mg
Heavy 35 mg +
Total 4 - 8 hours
Onset 20 - 60 minutes
Come up 1 - 2 hours
Peak 1.5 - 3 hours
Offset 1 - 2 hours
After effects 2 - 4 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


4-Acetoxy-N-methyl-N-isopropyltryptamine (abbreviated 4-AcO-MiPT and also known as mipracetin) is a synthetic psychedelic tryptamine. It is the acetylated form of 4-HO-MiPT (also known as miprocin) and is a higher homolog of 4-AcO-DMT, 4-AcO-MET and 4-AcO-DET. These substances are commonly hypothesized to act primarily as prodrugs for their respective hydroxylated counterparts (e.g. 4-HO-DMT, 4-HO-MET and 4-HO-DET), although there is on-going debate as to whether they possess their own innate activity.[citation needed]

There is very little information on the human pharmacology or toxicity of 4-AcO-MiPT, although analytical methods have been developed for its detection.[1][2] Today it is either used recreationally or as an entheogenic substance and is typically acquired through the use of online research chemical vendors. It remains relatively uncommon and has very little history of human usage.


4-AcO-MiPT, or 4-Acetoxy-N-isopropyl-N-methyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 4-AcO-MiPT is substituted at R4 of its indole heterocycle with an acetoxy (AcO) functional group CH3COO−. It also contains isopropyl and methyl chains bound to the terminal amine RN of its tryptamine backbone (MiPT).

4-AcO-MiPT is the N-substituted methisopropyl homologue of 4-HO-DMT (psilocin). 4-AcO-MiPT is the acetate ester analog of MiPT and the N-substituted methisopropyl analog of 4-AcO-DMT.[3]


Further information: Serotonergic psychedelic

Like with most psychedelic tryptamines, 4-AcO-MiPT is thought to act principally as a 5-HT2A partial agonist. The psychedelic effects are believed to come from 4-AcO-MiPT's binding efficacy at the 5-HT2A receptors.

However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Auditory effects

Multi-sensory effects

Transpersonal effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 4-AcO-MiPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 4-AcO-MiPT is a research chemical with very little history of human usage.

Anecdotal evidence suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

4-AcO-MiPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like with most psychedelics, it is most often thought to be self-regulating.

Tolerance to the effects of 4-AcO-MiPT is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 4-AcO-MiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 4-AcO-MiPT all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Due to its relative obscurity, the possession and sale of 4-AcO-MiPT is unscheduled in most countries.

  • Germany: 4-AcO-MiPT is controlled under the NpSG[5] (New Psychoactive Substances Act) as of July 18, 2019.[6] Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable.[7][8] The legislator considers it possible that orders of 4-AcO-MiPT are punishable as an incitement to place it on the market.[9]
  • Japan: 4-AcO-MiPT is a controlled substance in Japan effective March 25th, 2015.[10]
  • Sweden: 4-AcO-MiPT is classified as "health hazard" under the act "Lagen om förbud mot vissa hälsofarliga varor" (translated to the "Act on the Prohibition of Certain Goods Dangerous to Health"). The drug is listed in their regulation SFS 2005:733, making it illegal to sell or possess.[11]
  • Switzerland: 4-AcO-MiPT could be considered an ester analog of 4-HO-MiPT, which would make it illegal according to Buchstabe B.[12]
  • United Kingdom: 4-AcO-MiPT is a Class A drug in the UK as it is an ester of the drug 4-HO-MiPT, which is a Class A drug as a result of the tryptamine catch-all clause.[13]
  • United States: 4-AcO-MiPT is unscheduled in the United States. It may be considered an analogue of psilocin (4-HO-DMT) which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.[citation needed]

See also

External links



  1. Takahashi, M.; Nagashima, M.; Suzuki, J.; Seto, T.; Yasuda, I.; Yoshida, T. (2009). "Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry". Talanta. 77 (4): 1245–1272. doi:10.1016/j.talanta.2008.07.062. eISSN 1873-3573. ISSN 0039-9140. OCLC 01767116. PMID 19084633. 
  2. Noorizadeh, H.; Farmany, A.; Noorizadeh, M. (2012). "Application of GA–KPLS and L–M ANN calculations for the prediction of the capacity factor of hazardous psychoactive designer drugs". 21 (9): 2680–2688. doi:10.1007/s00044-011-9794-y. eISSN 1554-8120. ISSN 1054-2523. OCLC 57733023. 
  3. "Compound Summary: Mipracetin". PubChem. National Center for Biotechnology Information. 46783587. Retrieved August 20, 2020. 
  4. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  5. "Anlage NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  6. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. ISSN 0341-1095. 
  7. "§ 4 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  8. "§ 3 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  9. "Gesetzentwurf der Bundesregierung: Entwurf eines Gesetzes zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Deutscher Bundestag. May 30, 2016. p. 20. Drucksache 18/8579. 
  10. 危険ドラッグの成分16物質を新たに指定薬物に指定 (in Japanese), 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)], retrieved 2 May 2022 
  11. "Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor" (PDF) (in Swedish) (published October 18, 2005). October 6, 2005. SFS 2005:733. 
  12. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  13. "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved August 20, 2020.